Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 52886X107 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Balyasny Asset Management L.P.
13G/A
Amendment 4
|
10.0% |
8/14/2026
Event 6/30/2026
|
|
| Balyasny Asset Management L.P. | 10.0% | ||
| Bam GP LLC | 10.0% | ||
| Balyasny Asset Management Holdings LP | 10.0% | ||
| Dames GP LLC | 10.0% | ||
| Dmitry Balyasny | 10.0% | ||
|
Paradigm Biocapital Advisors LP
13G/A
Amendment 3
|
5.3% |
8/14/2026
Event 6/30/2026
|
|
| Paradigm BioCapital Advisors LP | 5.3% | ||
| Paradigm BioCapital Advisors GP LLC | 5.3% | ||
| Senai Asefaw, M.D. | 5.3% | ||
| Paradigm BioCapital International Fund Ltd. | 4.7% | ||
|
OrbiMed Advisors LLC
13G
|
4.1% |
8/14/2026
Event 6/30/2026
|
|
| OrbiMed Advisors LLC | 4.1% | ||
| OrbiMed Capital LLC | 1.0% | ||
|
Affinity Asset Advisors, LLC
13G/A
Amendment 2
|
8.4% |
8/13/2026
Event 6/30/2026
|
|
| Affinity Asset Advisors, LLC | 8.4% | ||
| Michael Cho | 8.4% | ||
| State Street Corp 13G | 5.5% |
8/7/2026
Event 6/30/2026
|
|
|
Balyasny Asset Management L.P.
13G/A
Amendment 3
|
9.7% |
5/15/2026
Event 3/31/2026
|
|
| Balyasny Asset Management L.P. | 9.7% | ||
| Bam GP LLC | 9.7% | ||
| Balyasny Asset Management Holdings LP | 9.7% | ||
| Dames GP LLC | 9.7% | ||
| Dmitry Balyasny | 9.7% | ||
|
Paradigm Biocapital Advisors LP
13G/A
Amendment 2
|
8.3% |
5/15/2026
Event 3/31/2026
|
|
| Paradigm BioCapital Advisors LP | 8.3% | ||
| Paradigm BioCapital Advisors GP LLC | 8.3% | ||
| Senai Asefaw, M.D. | 8.3% | ||
| Paradigm BioCapital International Fund Ltd. | 7.4% | ||
|
Suvretta Capital Management, LLC
13G
|
7.7% |
4/13/2026
Event 4/6/2026
|
|
| Suvretta Capital Management, LLC | 7.7% | ||
| Averill Master Fund, Ltd. | 6.5% | ||
| Aaron Cowen | 7.7% | ||
| Vanguard Group Inc 13G/A Amendment 1 | 0% |
3/27/2026
Event 3/13/2026
|
|
|
Balyasny Asset Management L.P.
13G/A
Amendment 2
|
9.9% |
2/17/2026
Event 12/31/2025
|
|
| Balyasny Asset Management L.P. | 9.9% | ||
| Bam GP LLC | 9.9% | ||
| Balyasny Asset Management Holdings LP | 9.9% | ||
| Dames GP LLC | 9.9% | ||
| Dmitry Balyasny | 9.9% | ||
|
Citadel Advisors LLC
13G/A
Amendment 3
|
7.4% |
2/17/2026
Event 12/31/2025
|
|
| Citadel Advisors LLC | 7.2% | ||
| Citadel Advisors Holdings LP | 7.2% | ||
| Citadel GP LLC | 7.2% | ||
| Citadel Securities LLC | 0% | ||
| Citadel Securities Group LP | 0.1% | ||
| Citadel Securities GP LLC | 0.1% | ||
| Kenneth Griffin | 7.4% | ||
|
Paradigm Biocapital Advisors LP
13G/A
Amendment 1
|
6.5% |
2/17/2026
Event 12/31/2025
|
|
| Paradigm BioCapital Advisors LP | 6.5% | ||
| Paradigm BioCapital Advisors GP LLC | 6.5% | ||
| Senai Asefaw, M.D. | 6.5% | ||
| Paradigm BioCapital International Fund Ltd. | 5.8% | ||
|
Frazier Life Sciences Public Fund, L.P.
13G/A
Amendment 2
|
5.1% |
2/13/2026
Event 12/31/2025
|
|
| Frazier Life Sciences Public Fund, L.P. | 5.1% | ||
| FHMLSP, L.P. | 5.1% | ||
| FHMLSP, L.L.C. | 5.1% | ||
| Frazier Life Sciences X, L.P. | 0.1% | ||
| FHMLS X, L.P. | 0.1% | ||
| FHMLS X, L.L.C. | 0.1% | ||
| Frazier Life Sciences XI, L.P. | 0.3% | ||
| FHMLS XI, L.P. | 0.3% | ||
| FHMLS XI, L.L.C. | 0.3% | ||
| Frazier Life Sciences XII, L.P. | 0.6% | ||
| FHMLS XII, L.P. | 0.6% | ||
| FHMLS XII, L.L.C. | 0.6% | ||
| James N. Topper | 0.1% | ||
| Patrick J. Heron | 0.1% | ||
| Vanguard Group Inc 13G | 5.3% |
1/30/2026
Event 12/31/2025
|
|
|
Affinity Asset Advisors, LLC
13G/A
Amendment 1
|
7.1% |
1/29/2026
Event 1/22/2026
|
|
| Affinity Asset Advisors, LLC | 7.1% | ||
| Michael Cho | 7.1% | ||
| BlackRock, Inc. 13G | 6.7% |
1/21/2026
Event 12/31/2025
|
|
| Janus Henderson Group PLC 13G/A Amendment 7 | 10.0% |
12/8/2025
Event 11/28/2025
|
|
|
Paradigm Biocapital Advisors LP
13G
|
5.0% |
11/20/2025
Event 11/13/2025
|
|
| Paradigm BioCapital Advisors LP | 5.0% | ||
| Paradigm BioCapital Advisors GP LLC | 5.0% | ||
| Senai Asefaw, M.D. | 5.0% | ||
| Paradigm BioCapital International Fund Ltd. | 4.4% | ||
|
Janus Henderson Group PLC
13G/A
Amendment 6
|
11.3% |
11/14/2025
Event 9/30/2025
|
|
| Janus Henderson Group PLC | 11.3% | ||
| Janus Henderson Biotech Innovation Master Fund Ltd | 7.6% | ||
|
Longitude Capital Partners IV, LLC
13G/A
Amendment 2
|
3.8% |
11/14/2025
Event 9/30/2025
|
|
| Longitude Capital Partners IV, LLC | 3.8% | ||
| Longitude Venture Partners IV, L.P. | 3.8% | ||
| Patrick G. Enright | 3.8% | ||
| Juliet Tammenoms Bakker | 3.8% | ||
|
Balyasny Asset Management L.P.
13G/A
Amendment 1
|
10.0% |
11/14/2025
Event 9/30/2025
|
|
| Balyasny Asset Management L.P. | 10.0% | ||
| Bam GP LLC | 10.0% | ||
| Balyasny Asset Management Holdings LP | 10.0% | ||
| Dames GP LLC | 10.0% | ||
| Dmitry Balyasny | 10.0% | ||
|
Vestal Point Capital, LP
13G/A
Amendment 1
|
7.5% |
11/14/2025
Event 9/30/2025
|
|
| Vestal Point Capital, LP | 7.5% | ||
| Ryan Wilder | 7.5% | ||
|
Integrated Core Strategies (US) LLC
13G/A
Amendment 2
|
3.2% |
11/7/2025
Event 9/30/2025
|
|
| Integrated Core Strategies (US) LLC | 2.8% | ||
| Millennium Management LLC | 3.2% | ||
| Millennium Group Management LLC | 3.2% | ||
| Israel A. Englander | 3.2% | ||
|
RA Capital Management, L.P.
13G
|
6.9% |
10/27/2025
Event 10/20/2025
|
|
| RA Capital Management, L.P. | 6.9% | ||
| Peter Kolchinsky | 6.9% | ||
| Rajeev Shah | 6.9% | ||
| RA Capital Healthcare Fund, L.P. | 6.9% | ||
| BlackRock, Inc. 13G/A Amendment 1 | 4.0% |
10/17/2025
Event 9/30/2025
|
|
|
Frazier Life Sciences Public Fund, L.P.
13G/A
Amendment 1
|
5.7% |
8/14/2025
Event 6/30/2025
|
|
| Frazier Life Sciences Public Fund, L.P. | 5.7% | ||
| FHMLSP, L.P. | 5.7% | ||
| FHMLSP, L.L.C. | 5.7% | ||
| Frazier Life Sciences Public Overage Fund, L.P. | 1.2% | ||
| FHMLSP Overage, L.P. | 1.2% | ||
| FHMLSP Overage, L.L.C. | 1.2% | ||
| Frazier Life Sciences X, L.P. | 0.2% | ||
| FHMLS X, L.P. | 0.2% | ||
| FHMLS X, L.L.C. | 0.2% | ||
| Frazier Life Sciences XI, L.P. | 0.4% | ||
| FHMLS XI, L.P. | 0.4% | ||
| FHMLS XI, L.L.C. | 0.4% | ||
| Frazier Life Sciences XII, L.P. | 0.8% | ||
| FHMLS XII, L.P. | 0.8% | ||
| FHMLS XII, L.L.C. | 0.8% | ||
| James N. Topper | 0.2% | ||
| Patrick J. Heron | 0.2% | ||
| Albert Cha | 0% | ||
| James Brush | 0% | ||
| Daniel Estes | 0% | ||
|
Janus Henderson Group PLC
13G/A
Amendment 5
|
11.1% |
8/14/2025
Event 6/30/2025
|
|
| Janus Henderson Group PLC | 11.1% | ||
| Janus Henderson Biotech Innovation Master Fund Ltd | 6.2% | ||
|
Balyasny Asset Management L.P.
13G
|
10.0% |
8/14/2025
Event 6/30/2025
|
|
| Balyasny Asset Management L.P. | 10.0% | ||
| Bam GP LLC | 10.0% | ||
| Balyasny Asset Management Holdings LP | 10.0% | ||
| Dames GP LLC | 10.0% | ||
| Dmitry Balyasny | 10.0% | ||
|
Citadel Advisors LLC
13G/A
Amendment 2
|
9.6% |
8/14/2025
Event 6/30/2025
|
|
| Citadel Advisors LLC | 9.6% | ||
| Citadel Advisors Holdings LP | 9.6% | ||
| Citadel GP LLC | 9.6% | ||
| Citadel Securities LLC | 0% | ||
| Citadel Securities Group LP | 0% | ||
| Citadel Securities GP LLC | 0% | ||
| Kenneth Griffin | 9.6% | ||
|
Vestal Point Capital, LP
13G
|
6.0% |
8/14/2025
Event 6/30/2025
|
|
| Vestal Point Capital, LP | 6.0% | ||
| Ryan Wilder | 6.0% | ||
|
Integrated Core Strategies (US) LLC
13G/A
Amendment 1
|
5.3% |
8/7/2025
Event 6/30/2025
|
|
| Integrated Core Strategies (US) LLC | 4.9% | ||
| Millennium Management LLC | 5.3% | ||
| Millennium Group Management LLC | 5.3% | ||
| Israel A. Englander | 5.3% | ||
|
Affinity Asset Advisors, LLC
13G
|
7.8% |
6/4/2025
Event 5/28/2025
|
|
| Affinity Healthcare Fund, LP | 7.8% | ||
| Affinity Asset Advisors, LLC | 7.8% | ||
|
Frazier Life Sciences Public Fund, L.P.
13G
|
9.9% |
6/4/2025
Event 5/28/2025
|
|
| Frazier Life Sciences Public Fund, L.P. | 6.8% | ||
| FHMLSP, L.P. | 6.8% | ||
| FHMLSP, L.L.C. | 6.8% | ||
| Frazier Life Sciences Public Overage Fund, L.P. | 1.5% | ||
| FHMLSP Overage, L.P. | 1.5% | ||
| FHMLSP Overage, L.L.C. | 1.5% | ||
| Frazier Life Sciences X, L.P. | 0.2% | ||
| FHMLS X, L.P. | 0.2% | ||
| FHMLS X, L.L.C. | 0.2% | ||
| Frazier Life Sciences XI, L.P. | 0.6% | ||
| FHMLS XI, L.P. | 0.6% | ||
| FHMLS XI, L.L.C. | 0.6% | ||
| Frazier Life Sciences XII, L.P. | 1.0% | ||
| FHMLS XII, L.P. | 1.0% | ||
| FHMLS XII, L.L.C. | 1.0% | ||
| James N. Topper | 9.9% | ||
| Patrick J. Heron | 9.9% | ||
| Albert Cha | 8.3% | ||
| James Brush | 8.3% | ||
| Daniel Estes | 1.5% | ||
|
D1 Capital Partners L.P.
13G/A
Amendment 1
|
2.9% |
5/15/2025
Event 3/31/2025
|
|
| D1 Capital Partners L.P. | 2.9% | ||
| Daniel Sundheim | 2.9% | ||
|
Janus Henderson Group PLC
13G/A
Amendment 4
|
13.7% |
5/14/2025
Event 3/31/2025
|
|
| Janus Henderson Group PLC | 13.7% | ||
| Janus Henderson Biotech Innovation Master Fund Ltd | 8.1% | ||
| Mizuho Financial Group, Inc. 13G/A Amendment 1 | 6.6% |
5/13/2025
Event 3/31/2025
|
|
|
Adage Capital Management, L.P.
13G/A
Amendment 2
|
0.7% |
5/12/2025
Event 3/31/2025
|
|
| Adage Capital Management, L.P. | 0.7% | ||
| Robert Atchinson | 0.7% | ||
| Phillip Gross | 0.7% | ||
|
Integrated Core Strategies (US) LLC
13G
|
5.8% |
4/28/2025
Event 4/22/2025
|
|
| Integrated Core Strategies (US) LLC | 5.8% | ||
| Millennium Management LLC | 5.8% | ||
| Millennium Group Management LLC | 5.8% | ||
| Israel A. Englander | 5.8% | ||
|
Eventide Asset Management, LLC
13G/A
Amendment 3
|
3.7% |
2/14/2025
Event 12/31/2024
|
|
| Eventide Asset Management, LLC | 3.7% | ||
| Finny Kuruvilla, M.D., Ph. D. | 3.7% | ||
| Robin C. John | 3.7% | ||
|
Janus Henderson Group PLC
13G/A
Amendment 3
|
13.1% |
2/14/2025
Event 12/31/2024
|
|
| Janus Henderson Group PLC | 13.1% | ||
| Janus Henderson Biotech Innovation Master Fund Ltd | 7.6% | ||
|
Omega Fund VI, L.P.
13G/A
Amendment 1
|
3.6% |
2/14/2025
Event 12/31/2024
|
|
| Omega Fund VI, L.P. | 3.6% | ||
| Omega Fund VI GP, L.P. | 3.6% | ||
| Omega Fund VI GP Manager, Ltd. | 3.6% | ||
| Claudio Nessi | 3.6% | ||
| Otello Stampacchia | 3.6% | ||
| Francesco Draetta | 3.6% | ||
| Mizuho Financial Group, Inc. 13G | 5.8% |
2/13/2025
Event 12/31/2024
|
|
|
Adage Capital Management, L.P.
13G/A
Amendment 1
|
6.7% |
2/12/2025
Event 12/31/2024
|
|
| Adage Capital Management, L.P. | 6.7% | ||
| Robert Atchinson | 6.7% | ||
| Phillip Gross | 6.7% | ||
| BlackRock, Inc. 13G | 5.5% |
2/4/2025
Event 12/31/2024
|
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 2 | 1.15 k | $3.89 k |
| 2026 Q2 | 146 | 89.5 M | $418 M |
| 2026 Q1 | 144 | 79.9 M | $459 M |
| 2025 Q4 | 150 | 76.5 M | $759 M |
| 2025 Q3 | 112 | 49.3 M | $328 M |
| 2025 Q2 | 92 | 42.2 M | $170 M |
| 2025 Q1 | 92 | 28.0 M | $100 M |
| 2024 Q4 | 91 | 29.5 M | $194 M |
| 2024 Q3 | 72 | 29.8 M | $270 M |
| 2024 Q2 | 63 | 26.6 M | $427 M |
| 2024 Q1 | 58 | 23.2 M | $362 M |
| 2023 Q4 | 34 | 16.2 M | $217 M |